Press Releases Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M2035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-14 pm EDT			5-day change	1st Jan Change
1.940 ^USD	-2.51%		-8.49%	-22.09%

May. 12	Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026
May. 11	Acurx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Press Releases

May. 12	Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update	PR
May. 04	Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026	PR
Apr. 30	Acurx Pharmaceuticals : ESCMID Poster Presentation “Preclinical Microbiome Evaluation of novel PolC-inhibitor compounds (Begum, et. al., April 2026)"	PU
Apr. 29	Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase	PR
Apr. 27	Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit	NE
Apr. 20	Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update	PR
Apr. 16	Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
Apr. 16	Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
Apr. 07	New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events	AQ
Apr. 04	New to The Street Announces Episode 741 Airing Tonight on Bloomberg Television at 6:30 PM EST Featuring Canton Networks, Acme Markets, Virtuix Holdings (VTIX), HPB, Jonas & Redman, Acurx Pharmaceuticals (ACXP), and FreeCast (CAST)	AQ
Mar. 30	Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors	PR
Mar. 13	Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update	PR
Mar. 09	Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection	PR
Feb. 16	Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update	PR
Feb. 02	USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors	PR
Nov. 18	Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals	PR
Nov. 12	Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update	PR
Nov. 10	Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens	PR
25-10-28	Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference	PR
25-10-27	Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update	PR
25-10-09	Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors	PR
25-09-30	Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection	PR
25-09-03	Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules	PR
25-08-28	Acurx Pharmaceuticals : Corporate Presentation dated September 2025	PU
25-08-12	Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update	PR